We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 29, 2020

Neoadjuvant Endocrine Therapy Compared With Neoadjuvant Chemotherapy in Premenopausal Patients With ER+, HER2−, Lymph Node+ Breast Cancer

Breast Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research
Efficacy of Neoadjuvant Endocrine Therapy Compared With Neoadjuvant Chemotherapy in Pre-Menopausal Patients With Oestrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Breast Cancer Res 2020 May 27;[EPub Ahead of Print], HJ Kim, WC Noh, ES Lee, YS Jung, LS Kim, W Han, SJ Nam, G- Gong, HJ Kim, SH Ahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading